# ECHELON-3 (NCT04404283)

> Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04404283
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Seagen, a wholly owned subsidiary of Pfizer
- Conditions: Diffuse Large B-cell Lymphoma
- Interventions: Brentuximab vedotin; Rituximab; Lenalidomide; Placebo
- Enrollment: 239
- Primary outcome: Overall survival (OS)

## Commentary we found

- YouTube: 14
- Podcasts: 10
- X threads: 8

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=echelon-3-nct04404283

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04404283", "email": "<work email>"}; the inbox owner confirms by the emailed link.